Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

转移性三阴性乳腺癌一线治疗的联合靶向疗法——一项II期临床试验，研究每周一次的紫杉醇纳米粒联合贝伐单抗治疗，随后进行贝伐单抗联合厄洛替尼维持靶向治疗。